Argenx
ARGX · NASDAQ
Bulios Fair Price
$983.15
0.7% downside
Current Price
$990.54
According to Bulios Fair Price, ARGX is currently trading close to its fair value. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Argenx SE is a biopharmaceutical company based in Belgium, focusing on the development and commercialization of innovative therapies for the treatment of autoimmune diseases and malignant tumors. The company specializes in the development of monoclonal antibodies and utilizes its technology platform for the discovery and development of new drug candidates. Argenx focuses on therapeutic areas such as immunology, hematology, and oncology, aiming to provide potential treatments for patients with severe diseases who have limited therapeutic options available. The company also collaborates with pharmaceutical partners on the development and commercialization of its products. Argenx SE could be suitable for investors seeking opportunities in the biotechnology and pharmaceutical industries, with an emphasis on innovative therapies for the treatment of serious diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
Karen Massey
Employees
1,863
Headquarters
Amsterdam
Upcoming events
Earnings
Upcoming earnings report